Univariate analysis
| Primary endpoint | |||
|---|---|---|---|
| Yes | No | p Value | |
| Sex | |||
| Male | 21 (56.8%) | 16 (43.2%) | 0.74 |
| Female | 20 (60.6%) | 13 (39.4%) | |
| Race | |||
| Caucasian | 36 (56.3%) | 28 (43.8%) | 0.39 |
| Other | 5 (83.3%) | 1 (16.7%) | |
| Seton | |||
| Yes | 9 (60%) | 6 (40%) | 0.90 |
| No | 32 (58.2%) | 23 (41.8%) | |
| Stoma | |||
| Yes | 8 (72.7%) | 3 (27.3%) | 0.30 |
| No | 33 (55.9%) | 26 (44.1%) | |
| Tobacco | |||
| Yes | 12 (54.5%) | 10 (45.5%) | 0.64 |
| No | 29 (60.4%) | 19 (39.6%) | |
| Previous IFX | |||
| Yes | 15 (62.5%) | 9 (37.5%) | 0.63 |
| No | 26 (56.5%) | 20 (43.5%) | |
| Corticosteroids | |||
| Yes | 2 (50%) | 2 (50%) | 0.72 |
| No | 39 (59.1%) | 27 (40.9%) | |
| AZA/6MP/MTX | |||
| Yes | 12 (48.0%) | 13 (52.0%) | 0.18 |
| No | 29 (46.4%) | 16 (35.6%) | |
IFX, infliximab; AZA, azathioprine; 6MP, 6-mercaptopurine, MTX, methotrexate.